Quarterly ResultAug 6, 2026, 07:01 AM
Avalo to start Phase 3 abdakibart in HS; cash runway into 2029
AI Summary
Avalo Therapeutics announced plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027. The company also expanded its pipeline with AVTX-010, a long-acting anti-IL-1β antibody, with an IND submission planned for the first half of 2027. Avalo reported cash, cash equivalents, and investments of $472.2 million as of June 30, 2026, providing a projected cash runway into 2029. Additionally, Ron Philip was appointed to the Board of Directors, and the company was added to the Russell 2000® and Russell 3000® Indexes.
Key Highlights
- Plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in H1 2027.
- IND submission planned for AVTX-010, a next-generation anti-IL-1β antibody, in H1 2027.
- Appointed Ron Philip to the Board of Directors.
- Cash, cash equivalents, and investments totaled $472.2 million as of June 30, 2026.
- Expected cash runway into 2029.
- Research and development expenses were $23.4 million for Q2 2026, up $9.3 million YoY.
- Net loss was $36.4 million for Q2 2026, an increase of $15.6 million YoY.
- Added to the Russell 2000® and Russell 3000® Indexes.
Price Impact
More from AVTX